A recent study conducted at the University of Athens Pharmacy Department has revealed the potential of laboratory-modified cannabis in reducing cancer cells and mitigating side effects associated with chemotherapy.
The research focused on cannabinoid acids found in cannabis, which demonstrated a significant reduction in breast, liver, and skin cancer cells after undergoing specific modifications in the lab. These compounds exhibited enhanced penetration into cell membranes and fatty tissues and improved stability inside and outside the body, suggesting more promising pharmacological effects. Notably, cannabigerol acid butyl ester (CBG) showcased the most promising results against breast cancer cells. It was found to be non-toxic and non-psychoactive in animal experiments, even at high doses. The results shed light on the potential of laboratory-modified cannabis in combating cancer cells while addressing the side effects associated with traditional chemotherapy and are now the subject of a patent.
Currently, two preparations containing medicinal cannabis have been approved: epidyolex, which is a complementary treatment for epileptic seizures and contains cannabidiol (CBD), and Sativex for the treatment of spasticity and neuropathic pain and which combines tetrahydrocannabinol (THC) and CBD.
The findings of this study, reported here, were presented by Associate Professor Prokopios Magiatis of the University of Athens Laboratory of Pharmacognosy and Natural Products Chemistry, at the 9th Panhellenic Conference of Applied Sciences.
Greetings! Very helpful advice in this particular article! It is the little changes that will make the largest changes. Many thanks for sharing!